The Past and the Future of Alzheimer’s Disease Fluid Biomarkers

Serum neurofilament light in familial Alzheimer disease

(2017) Philip S.J. Weston et al.   NEUROLOGY

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease

(2017) Niklas Mattsson et al.   JAMA Neurology

Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status

(2016) Laura Piccio et al.   ACTA NEUROPATHOLOGICA

Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1–42) in human cerebrospinal fluid

(2016) Tobias Bittner et al.   Alzheimers & Dementia

Round robin test on quantification of amyloid-β 1–42 in cerebrospinal fluid by mass spectrometry

(2016) Josef Pannee et al.   Alzheimers & Dementia

TDP-43 stage, mixed pathologies, and clinical Alzheimer’s-type dementia

(2016) Bryan D. James et al.   BRAIN

Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography

(2016) Sebastian Palmqvist et al.   BRAIN

Assessing the commutability of reference material formats for the harmonization of amyloid-β measurements

(2016) Maria Bjerke et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa

(2016) Jens Kuhle et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers

(2016) Marc Suárez‐Calvet et al.   EMBO Molecular Medicine

Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer’s Disease

(2016) Piotr Lewczuk et al.   JOURNAL OF ALZHEIMERS DISEASE

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

(2016) Bob Olsson et al.   LANCET NEUROLOGY

Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer′s and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies

(2016) Patrick Oeckl et al.   MOLECULAR & CELLULAR PROTEOMICS

Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease

(2016) Nour K. Majbour et al.   Molecular Neurodegeneration

Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease

(2016) Amanda Heslegrave et al.   Molecular Neurodegeneration

Plasma tau in Alzheimer disease

(2016) Niklas Mattsson et al.   NEUROLOGY

Increased CSF neurogranin concentration is specific to Alzheimer disease

(2016) Henrietta Wellington et al.   NEUROLOGY

Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia

(2016) Jonathan D. Rohrer et al.   NEUROLOGY

The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease

(2016) Annika Öhrfelt et al.   Alzheimers Research & Therapy

Plasma neurofilament light chain predicts progression in progressive supranuclear palsy

(2016) Julio C. Rojas et al.   Annals of Clinical and Translational Neurology

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease

(2016) Shorena Janelidze et al.   Annals of Clinical and Translational Neurology

Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study

(2016) Magnus Gisslén et al.   EBioMedicine

Plasma β-amyloid in Alzheimer’s disease and vascular disease

(2016) Shorena Janelidze et al.   Scientific Reports

Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease

(2015) Hlin Kvartsberg et al.   Alzheimers & Dementia

Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research

(2015) Sid E. O'Bryant et al.   Alzheimers & Dementia

C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease

(2015) Ann De Vos et al.   Alzheimers & Dementia

Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study

(2015) Massimo S. Fiandaca et al.   Alzheimers & Dementia

Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer’s disease

(2015) Erik Portelius et al.   BRAIN

A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes

(2015) N K Magdalinou et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Understanding Biomarkers of Neurodegeneration: Ultrasensitive detection techniques pave the way for mechanistic understanding

(2015) Kaj Blennow et al.   NATURE MEDICINE

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease

(2015) Sebastian Palmqvist et al.   NEUROLOGY

Amyloid biomarkers in Alzheimer's disease

(2015) Kaj Blennow et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls

(2015) Hlin Kvartsberg et al.   Alzheimers Research & Therapy

Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer’s disease

(2015) Konstantin Hellwig et al.   Alzheimers Research & Therapy

Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study

(2015) Julien Dumurgier et al.   Alzheimers Research & Therapy

Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease

(2015) Maartje I. Kester et al.   JAMA Neurology

Plasma Aβ but Not Tau is Related to Brain PiB Retention in Early Alzheimer’s Disease

(2014) Kai-Yuan Tzen et al.   ACS Chemical Neuroscience

Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease

(2014) Niklas Mattsson et al.   BRAIN

Mass Spectrometry-Based Candidate Reference Measurement Procedure for Quantification of Amyloid-  in Cerebrospinal Fluid

(2014) A. Leinenbach et al.   CLINICAL CHEMISTRY

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

(2014) Bruno Dubois et al.   LANCET NEUROLOGY

SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease

(2014) Ann Brinkmalm et al.   Molecular Neurodegeneration

The amyloid-β degradation pattern in plasma—A possible tool for clinical trials in Alzheimer's disease

(2014) Josef Pannee et al.   NEUROSCIENCE LETTERS

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease

(2014) Oskar Hansson et al.   Alzheimers Research & Therapy

Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β-Amyloid 42

(2014) Sebastian Palmqvist et al.   JAMA Neurology

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease

(2014) Niklas Mattsson et al.   Annals of Clinical and Translational Neurology

CSF biomarker variability in the Alzheimer's Association quality control program

(2013) Niklas Mattsson et al.   Alzheimers & Dementia

Neurotransmitter Release: The Last Millisecond in the Life of a Synaptic Vesicle

(2013) Thomas C. Südhof   NEURON

Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer’s Disease

(2013) Jere E. Meredith Jr. et al.   PLoS One

Plasma tau levels in Alzheimer's disease

(2013) Henrik Zetterberg et al.   Alzheimers Research & Therapy

Amyloid plaque formation precedes dendritic spine loss

(2012) Tobias Bittner et al.   ACTA NEUROPATHOLOGICA

Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium

(2012) Maria C. Carrillo et al.   Alzheimers & Dementia

Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders

(2012) Sara Hall et al.   ARCHIVES OF NEUROLOGY

Clinical Chemistry and Laboratory Medicine: an appreciation

(2012) Graham H. Beastall et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010

(2012) Thomas G. Beach et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Molecular machines governing exocytosis of synaptic vesicles

(2012) Reinhard Jahn et al.   NATURE

TREM2 Variants in Alzheimer's Disease

(2012) Rita Guerreiro et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers

(2011) Niklas Mattsson et al.   Alzheimers & Dementia

The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Guy M. McKhann et al.   Alzheimers & Dementia

The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Marilyn S. Albert et al.   Alzheimers & Dementia

Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias

(2011) Lucilla Parnetti et al.   MOVEMENT DISORDERS

Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia

(2011) William E. Klunk   NEUROBIOLOGY OF AGING

Hypoxia Due to Cardiac Arrest Induces a Time-Dependent Increase in Serum Amyloid β Levels in Humans

(2011) Henrik Zetterberg et al.   PLoS One

DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease

(2010) Zhen Hong et al.   BRAIN

Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease

(2010) Annika Thorsell et al.   BRAIN RESEARCH

Changes in dendritic complexity and spine morphology in transgenic mice expressing human wild-type tau

(2010) Dara L. Dickstein et al.   Brain Structure & Function

Biomarkers in Alzheimer's disease drug development

(2010) Kaj Blennow   NATURE MEDICINE

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

(2010) Kaj Blennow et al.   Nature Reviews Neurology

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

(2009) Leslie M. Shaw et al.   ANNALS OF NEUROLOGY

CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment

(2009) Niklas Mattsson   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study

(2009) Pieter Jelle Visser et al.   LANCET NEUROLOGY

Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease

(2009) Joseph L. Price et al.   NEUROBIOLOGY OF AGING

Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau181P

(2009) Karen Koopman et al.   NEUROCHEMISTRY INTERNATIONAL

Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation

(2008) Laura Piccio et al.   BRAIN

Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment

(2008) Oskar Hansson et al.   NEUROBIOLOGY OF AGING

Cerebrospinal fluid α-synuclein in neurodegenerative disorders—A marker of synapse loss?

(2008) Annika Öhrfelt et al.   NEUROSCIENCE LETTERS